Group items matching

in title, tags, annotations or url

The program seeks to fund research directed at understanding the fundamental characteristics and biological mechanisms of brain function and disfunction, as well as the translation of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Of particular interest is research dedicated to schizophrenia and/or depression. Studies that use exiting data and collaborations to accelerate discovery and knowledge also are encouraged.

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.

Founded in 1972, the Tourette Association of America has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders. To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies related to any aspect of Tourette syndrome. To be eligible, investigators are required to have an advanced degree such as a PhD, MD, or equivalent or be an allied professional with an advanced degree in a related field. Investigators from nonprofit and for-profit organizations are eligible to apply. Pre-proposals must be received no later than November 1, 2017. Upon review, selected applicants will be invited to submit a full application by February 15, 2018.

Rotary International is accepting applications for its CART Fund, a program designed to encourage exploratory and developmental Alzheimer's disease research projects within the United States. To that end, the fund will award grants of up to $250,000 to support for early and conceptual plans of those projects that may not yet be supported by extensive preliminary data but have the potential to substantially advance biomedical research. These projects should be new and distinct from those designed to increase knowledge in a well-established area unless they intend to extend previous discoveries toward new directions or applications. Eligible applications may come from full time faculty (or equivalent status) at U.S.-based public and private institutions, such as universities, colleges, hospitals, and laboratories.

Chronic Brain Injury is accepting seed grant proposals from cross-college teams of faculty studying topics related to traumatic brain injury, concussion and dementia, including Alzheimer's disease. Five awards of $25,000 are available, and all Ohio State faculty are eligible.

To that end, the foundation will award up to $50,000 in support of innovative research, with a focus on exercise and/or nutrition and Parkinson's disease. The topic of the research can be interpreted to include a range of investigations, including effects on speech, falls, and non-motor symptoms.  

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

This RFA invites applications for planning awards to develop and finalize protocols for well-powered cognitive training intervention trials to remediate or prevent age-related cognitive decline as well as possibly prevent or delay the onset of mild cognitive impairment and dementia. Planning activities may include the collection of pilot data and the refinement of cognitive training protocols consistent with Stage I of the NIH Stage Model. Trial designs must justify the means used to assess cognition and to explore the underlying mechanisms of change. Such methods as structural and functional neuroimaging with biomarkers justified by an underlying model of change, CSF fluids, and blood biomarkers are appropriate candidate tools.

The Chan Zuckerberg Initiative invites applications to join the CZI Neurodegeneration Challenge Network an interdisciplinary collaborative initiative to increase understanding of the fundamental biology of neurodegenerative disorders. Applications are being accepted for two funding mechanisms: Awards are worth $350K total costs per year for three years, for a total of $1.05M (including up to 15% indirect costs). The CZI Neurodegeneration Challenge Network has three goals: (1) to make fundamental advances toward understanding neurodegeneration; (2) to bring new ideas and talent to the field of neurodegeneration; and (3) to encourage a new type of interdisciplinary collaborative research involving scientists, clinicians and engineers

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

CZI Ben Barres Early Career Acceleration Awards: five-year investigator grants for early career academic investigators, with an emphasis on those who are new to the field of neurodegeneration. We seek to empower investigators to pursue bold ideas and to take risks within a supportive and collaborative environment. Awardees will benefit from mentorship support, as well as professional development, training and network opportunities, and practical career guidance to help them navigate this early stage of their careers.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

This Funding Opportunity Announcement (FOA) invites applications to design and implement research infrastructure that will enable the monitoring of cognitive abilities and age, state, context, or health condition-related changes in cognitive abilities on mobile devices. This effort will include the development (or support for development) of apps on the Android and iOS platforms, the validation of tests and items to be used on the two leading smartphone platforms in age groups ranging from 20 to 85, and the norming of successfully validated measures to nationally representative U.S. population samples that will also receive gold standard measures, including the NIH Toolbox® for Assessment of Behavioral and Neurological Function. A goal of this project is to also support data collection efforts from participants enrolled in projects awarded through this FOA as well as other NIH-funded studies though FY2022, and enable the widespread sharing of both the collected data and the test instruments.

This Funding Opportunity Announcement (FOA) invites applications to design and implement research infrastructure that will enable the monitoring of cognitive abilities and age, state, context, or health condition-related changes in cognitive abilities on mobile devices. This effort will include the development (or support for development) of apps on the Android and iOS platforms, the validation of tests and items to be used on the two leading smartphone platforms in age groups ranging from 20 to 85, and the norming of successfully validated measures to nationally representative U.S. population samples that will also receive gold standard measures, including the NIH Toolbox for Assessment of Behavioral and Neurological Function. A goal of this project is to also support data collection efforts from participants enrolled in projects awarded through this FOA as well as other NIH-funded studies though FY2022, and enable the widespread sharing of both the collected data and the test instruments.

The PRARP Convergence Science Research Award (CSRA) mechanism was first offered in FY12. Since then, 195 CSRA applications have been received, and 36 have been recommended for funding. The intent of the FY17 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP's mission (see Section II.A, Program Description). The FY17 PRARP CSRA is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years.

It is anticipated that Part 15, Contracting by Negotiations will be used and a single Cost Reimbursement, Level of Effort type contract will be awarded for one 12-month base period and four 12-month option periods on or about 08/06/2018. The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as PET, SPECT, and fMRI ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds).

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson's with GBA will award one-to-two-year grants for GBA research to advance understanding of GBA biology and accelerate therapeutic approaches. This program seeks proposals for research studying: * How GBA mutations lead to PD * Mechanisms underlying GCase dysfunction in the absence of GBA mutations * Novel therapeutic interventions to prevent pathogenic mechanisms triggered by GCase-pathway dysfunction Mutations in the glucocerebrosidase (GBA) gene are one of the most common risk factors for Parkinson's disease. GBA encodes a lysosomal enzyme, beta-glucocerebrosidase (GCase). Reduced GCase activity is associated with GBA mutations and has been reported in idiopathic PD, suggesting a more general role for GCase pathway dysfunction in Parkinson's. The exact cellular mechanism by which GCase deficits contribute to the pathogenesis of PD remains unclear, warranting further investigation. Pre-proposal due May 31.

Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment. Any proposal must have a clear focus on Alzheimer's disease and related disorder and be translational in nature. All proposals should clearly and explicitly outline the measure to be investigated, the methods for study, and outcomes. Researchers from underrepresented groups are encouraged to apply.

This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimers Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.

Through the program, grants of up to $3 million over three years will be awarded to established investigators across scientific disciplines and geographies who are positioned to make major advances in understanding the heterogeneity of systemic lupus erythematous (SLE) using highly collaborative, synergistic, and innovative approaches.